Tiziana Life Sciences
  • Our Company
    • Our Company
    • About us
    • Our Team
  • Technology
  • Pipeline
    • Intranasal Foralumab
      • Secondary Progressive Multiple Sclerosis
      • Alzheimer’s Disease
      • Other Indications
    • Anti IL-6R (TZLS-501)
    • Milciclib (TZLS-201)
  • Investors, News & Media
    • News
    • Media
    • Publications
    • Investors
  • Contact
Select Page

Secondary Progressive Multiple Sclerosis

Recent Posts

  • Tiziana Life Sciences Appoints New Chief Executive Officer
  • Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
  • Tiziana Life Sciences Granted FDA Fast Track Designation
  • FDA clears foralumab nasal spray for expanded use in Alzheimer’s
  • Tiziana Receives $3.4 Million in Non-Dilutive Funding

Recent Comments

No comments to show.

Tiziana Life Sciences, Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda  |  info@tizianalifesciences.com   |  +44 (0) 207 495 2379

  • Follow
  • Follow

© Tiziana Life Sciences 2024  |   Legal  |  Privacy Policy

NASDAQ: TLSA